HM Sanchinarro

The oncology team at HM Sanchinarro is evaluating a novel targeted agent for patients with locally advanced or metastatic non‑small cell lung cancer that carries an EGFR exon‑20 insertion mutation. The study aims to compare anti‑tumor activity against standard platinum‑based chemotherapy.

• Assess anti‑tumor efficacy of the investigational drug
• Compare outcomes with platinum‑based doublet chemotherapy
• Focus on treatment‑naïve patients

Findings could expand therapeutic options for this genetically defined lung cancer subgroup.

Researchers are testing the safety of NG‑641 together with a PD‑1 inhibitor such as nivolumab in people with metastatic or advanced epithelial tumours. The early‑phase trial seeks to identify a tolerable dose and gather initial efficacy signals.

• Characterise safety and tolerability of the combination
• Determine recommended dose for further development
• Include patients with diverse epithelial cancer types

Successful results would support continued investigation of this novel immunotherapy pairing.

A separate study examines NG‑350A in combination with pembrolizumab for individuals with metastatic or advanced epithelial tumours. The primary goal is to establish safety, tolerability, and an appropriate dose for future trials.

• Assess safety profile of NG‑350A plus pembrolizumab
• Identify optimal dosing for subsequent research
• Target a broad range of epithelial cancers

This work aims to broaden immunotherapeutic strategies for patients with hard‑to‑treat cancers.